Very interesting! Alan
Nucleoside analogs have been proposed as efficient therapeutic agents for the treatment of viral diseases and cancer. Though their therapeutic potential has been realized for many years, their clinical applicability remains questionable. This can be attributed to the challenges associated with combining it with suitable carrier molecules.
The therapeutic manifestation of a nucleoside analog is subject to the presence of carrier molecules that can escort it inside the cell (via the lipoproteinous membrane) and help in the process of its cellular activation. Hence, scientists started working on the development of biomolecules that can perform the same task even in the absence of carrier molecules. Scientists propose that the new pronucleotide (ProTide) molecules may be the answer to this dilemma.
According to a recent publication in Science, these pronucleotides can cross the bio-membrane without any carrier molecule and can perform the same function as that of nucleoside analogs. Furthermore, they are also immune against degradation by host cell enzymes. This makes them a potential candidate for the production and application of molecular drugs for clinical.